Results of the L-MIND trial in R/R DLBCL


During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to our Chair, Gilles Salles, from South Lyon University Hospital Complex, Lyon, FR, about the results of the L-MIND trial in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Gilles Salles discusses how the L-MIND trial assesses the efficacy of the combination of an enhanced CD19 antibody and lenalidomide for patients with R/R DLBCL. He mentioned how the duration of the response was now close to 22 months, indicating a significant benefit for patients who are often difficult to treat.

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF